Clinical trials: CNV
Polypoidal Choroidal Vasculopathy
Intravitreal Aflibercept Injection for Polypoidal Choroidal Vasculopathy With Hemorrhage or Exudation
To evaluate the efficacy and safety of intravitreal aflibercept injection in the treatment of PCV
- Trial name
- EPIC (NCT01871376)
- Testing
- Intravitreal aflibercept injection 2.0mg
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Gregg T. Kokame, MD
Choroidal Neovascularization, Presumed Ocular Histoplasmosis
Intravitreal Aflibercept Injection (IAI) for Presumed Ocular Histoplasmosis Syndrome
The purpose of this study is to assess the efficacy and safety of intravitreal injection of aflibercept for the treatment of Choroidal Neovascularization (CNV) secondary to presumed ocular histoplasmosis syndrome (POHS).
- Trial name
- NCT01578720
- Testing
- EYLEA (Aflibercept) intravitreal injection
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Retina Research Institute, LLC
Macular Degeneration, Histoplasmosis
Submacular Surgery Trials (SST)
To determine whether surgical removal of subfoveal choroidal neovascularization (CNV) and associated hemorrhage in patients with age-related macular degeneration (AMD), the ocular histoplasmosis syndrome (OHS), or idiopathic CNV…
- Trial name
- NCT00000150
- Testing
- Subfoveal Choroidal Neovascularization Removal
- Sponsor
- National Eye Institute (NEI)
Choroidal Neovascularization, Age-related Macular Degeneration
Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
The purpose of this study is to evaluate the safety, biological activity and pharmacodynamic effect of repeated intravitreal doses of hI-con1 0.3 mg administered as monotherapy and in combination with ranibizumab 0.5 mg compared…
- Trial name
- EMERGE (NCT02358889)
- Testing
- hI-con1, ranibizumab
- Where
- 48 sites in United States
- Volunteers
- 88 people
- Sponsor
- Iconic Therapeutics, Inc.
Age-Related Macular Degeneration
Study of PF-04523655 (REDD14NP) In Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (Wet AMD)
The aim of the study is to evaluate whether PF-04523655 is safe in the treatment of neovascular/wet AMD
- Trial name
- NCT00725686
- Testing
- PF-04523655
- Where
- 11 sites in United States, Israel
- Volunteers
- 54 people
- Sponsor
- Quark Pharmaceuticals
Age-Related Macular Degeneration, Neovascularization, Choroidal
Comparison of Ranibizumab Monotherapy and Ranibizumab Combination Therapies in Recurrent or Persistent Choroidal Neovascularization Secondary to Age-related Macular Degeneration
Age-related macular degeneration (AMD) is by far the most common disorder in the group of irreversible causes of visual disability. AMD leads to dysfunction and loss of photoreceptors in the central retina.
- Trial name
- NCT01162746
- Testing
- Intravitreal dexamethasone and intravitreal ranibizumab, Intravitreal ranibizumab
- Where
- Austria
- Volunteers
- 40 people
- Sponsor
- Medical University of Vienna
Choroidal Neovascularization, Choroid Disease
Treatment of Polypoidal Choroidal Vasculopathy in Pachychoroid
This study will evaluate patients with diagnosis of polypoidal choroidal vasculopathy (PCV) in pachychoroid treated with combined therapy, consisting in photodynamic therapy (PDT) and 3 intravitreal therapy (IVT) of Aflibercept…
- Trial name
- NCT04075188
- Testing
- Aflibercept Injection
- Where
- Italy
- Volunteers
- 17 people
- Sponsor
- Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo
Genetic Disease, CNV
Reinterpretation of CNV With Unknown Significance: a 5-year Retrospective Analysis
We aim to assess the usefulness of systematic reinterpretation of CNV of unknown significance. To investigate this question we will study all CNV of unknown significance detected between 2010 and 2017.
- Conditions
- Genetic Disease, CNV, Genetic Counseling, Array CGH
- Trial name
- ReAC (NCT04575350)
- Testing
- reinterpretation of CNV
- Where
- France
- Volunteers
- 282 people, healthy volunteers welcome
- Sponsor
- Central Hospital, Nancy, France
Age Related Macular Degeneration
Usability of the Foresee Home in Intermediate Age Related Macular Degeneration (AMD) Patients
The study purpose is to demonstrate that the target population can receive a packed FORESEE HOME unpack it, install and operate it to an extent that the FORESEE HOME can monitor them for changes in the visual field with good…
- Trial name
- UU2 (NCT00748384)
- Where
- 2 sites in Israel
- Volunteers
- 30 people
- Sponsor
- Notal Vision Ltd.
Choroidal Neovascularization, Punctate Inner Choroidopathy
Long-term Outcome of Punctate Inner Choroidopathy or Multifocal Choroiditis With Active Choroidal Neovascularization Managed With Anti-vascular Endothelial Growth Factor
To evaluate the long-term outcome of active choroidal neovascularization (CNV) in punctate inner choroidopathy (PIC) or multifocal choroiditis (MFC) after anti-vascular endothelial factor treatment.
- Trial name
- NCT03793400
- Testing
- Bevacizumab Injection
- Where
- Taiwan
- Volunteers
- 22 people
- Sponsor
- Changhua Christian Hospital
Neovascular Age-related Macular Degeneration
Long-term Results After Intravitreal Bevacizumab Treatment Of Neovascular Age-related Macular Degeneration
200 eyes with each subtype of neovascular age-related macular degeneration will be included in this study and 3 years after the initial intravitreal bevacizumab, best-corrected visual acuity (BCVA) will be measured using Snellen…
- Trial name
- NCT01027468
- Testing
- Bevacizumab
- Volunteers
- 160 people
- Sponsor
- Medical University of Vienna
Choroidal Neovascularisation, Polypoidal Choroidal Vasculopathy
Off-Label AVASTIN (BEVACIZUMAB) For Serosanguinous Maculopathy
To assess the use of Avastin for the management of serosanguinous maculopathy
- Trial name
- NCT00344617
- Testing
- Bevacizumab (tradename: Avastin)
- Volunteers
- 50 people
- Sponsor
- Singapore National Eye Centre
Macular Degeneration
A Study of rhuFab V2 (Ranibizumab) in Subjects With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)
This is a phase III, multicenter, randomized, double masked, sham injection-controlled study of the efficacy and safety of intravitreally administered ranibizumab in subjects with subfoveal choroidal neovascularization secondary…
- Trial name
- NCT00090623
- Testing
- rhuFab V2 (ranibizumab)
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- Genentech, Inc.
Exudative Age-related Macular Degeneration
Indocyanine Angiographic Changes of Choroidal Neovascularization by Ranibizumab
Exudative age-related macular degeneration (ARMD) is complicated by choroidal neovascularization (CNV). Although anti-vascular endothelial growth factor treatment is the gold standard treatment, recurrence is the main limitation…
- Trial name
- NCT01810042
- Testing
- ranibizumab
- Where
- 2 sites in South Korea
- Volunteers
- 49 people
- Sponsor
- Pusan National University Hospital
Choroidal Neovascularization, Age-related Macular Degeneration
A Study to Evaluate Ranibizumab in Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)
This is a Phase IIIb, single-masked, 1-year multicenter study of the safety and tolerability of intravitreally administered ranibizumab in subjects with active subfoveal CNV secondary to AMD.
- Trial name
- NCT00251459
- Testing
- rhuFab V2 (ranibizumab)
- Volunteers
- 5,000 people
- Sponsor
- Genentech, Inc.
Macular Degeneration
Phase II Pilot Study of Visudyne® Photodynamic Therapy (PDT) (Low and Very Low Fluence) Combined With Bevacizumab.
To determine if Visudyne photodynamic therapy (low or very low fluence rate) combined with intravitreal injections of bevacizumab (Avastin) compared with bevacizumab alone will, with similar safety and efficacy, delay time to…
- Trial name
- NCT00359164
- Testing
- Verteporfin Photodynamic Therapy (Low Fluence) and bevacizumab, Verteporfin Photodynamic Therapy (Very Low Fluence) and bevacizumab
- Where
- Canada
- Volunteers
- 36 people
- Sponsor
- University of British Columbia
Neovascular Polypoidal Choroidal Vasculopathy
Intravitreal Aflibercept for Neovascular Polypoidal Choroidal Vasculopathy (RIVAL Trial)
The purpose of this study is to evaluate the safety and efficacy of intravitreal aflibercept injection (IAI) in patients with neovascular polypoidal choroidal vasculopathy.
- Trial name
- RIVAL (NCT02092532)
- Testing
- Rescue Intravitreal Aflibercept Injection, Rescue Therapy with PDT, Laser or Intravitreal Steroids
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Southeast Retina Center, Georgia
Age-related Macular Degeneration, Choroidal Neovascularization
Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration
The purpose of this study is to determine the safety and efficacy of an ocular sirolimus (rapamycin) formulation via different injection routes in patients with treatment-naive sub-foveal choroidal neovascularization secondary to…
- Trial name
- NCT00712491
- Testing
- Sirolimus
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Santen Inc.
Myopic Choroidal Neovascularization
Ranibizumab for Myopic Neovascularization
The purpose of this study is to evaluate the clinical results of anti-VEGF intra-vitreal injections (IVT) in CNV secondary to pathologic myopia (PM-CNV).
- Trial name
- NCT01246089
- Testing
- ranibizumab injection
- Where
- Brazil
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Instituto de Olhos de Goiania
Choroidal Neovascularization
Ranibizumab in Hemorrhagic Choroidal Neovascularization Trial
This research is being done to look at the effects of an experimental drug, ranibizumab, on a condition called "predominantly hemorrhagic subfoveal choroidal neovascularization (CNV)" due to wet age-related macular degeneration.
- Trial name
- NCT00363168
- Testing
- Ranibizumab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Johns Hopkins University